Supplements and Featured Publications
Parkinson’s Disease Psychosis: Symptoms, Management, and Economic Burden
Volume 21
Issue 10 Suppl

Participating Faculty: Parkison's Disease Psychosis: Symptoms, Management, and Economic Burden

The publication of this article was supported by ACADIA Pharmaceuticals Inc. The views and opinions expressed are those of the authors and not necessarily those of ACADIA Pharmaceuticals Inc.


Neal Hermanowicz, MD

Director, Movement Disorders Program

Vice-Chair for Clinical Affairs

Department of Neurology

University of California, Irvine

Kari Edwards, PhD

Principal, Health Economics and Market Access

ICON plc Commercialisation and Outcomes

Los Angeles, California

Faculty Disclosures

These faculty report relationships with the following organizations:

Neal Hermanowicz, MD, has disclosed the following relevant commercial financial relationships or affiliations in the past 12 months:

Advisory board, consultant honoraria, and lecture fees: ACADIA Pharmaceuticals Inc.

Kari Edwards, PhD, has no relevant financial relationships with commercial interests to disclose.

Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey.

Parkinson’s disease psychosis (PDP) is a costly, debilitating condition that generally develops several years after diagnosis of Parkinson’s disease (PD). The neuropsychiatric symptoms that are common in PD can be a significant source of distress to patients and caregivers. This supplement to The American Journal of Managed Care presents managed care decision makers with information on the long-term care utilization by patients with PDP and the overall economic burden associated with PDP.

CH LogoCenter for Biosimilars Logo